2018
Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place
Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review Of Hematology 2018, 11: 715-726. PMID: 30024293, DOI: 10.1080/17474086.2018.1503049.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmunosuppressive therapyMyelodysplastic syndromeImmune pathwaysManagement of MDSTreatment of MDSClonal hematopoietic stem cell disordersMeaningful clinical activityAdaptive immune pathwaysHematopoietic stem cell disordersStem cell disordersImmune dysregulationDisease coursePeripheral cytopeniasClinical benefitImmune activationTherapeutic optionsAplastic anemiaClinical activityHematologic diseasesCell disordersClinical experienceContinued clarificationLeukemic progressionTherapyPatients
2015
Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine
Zeidan AM, Al Ali N, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clinical Lymphoma Myeloma & Leukemia 2015, 15: 705-710. PMID: 26440749, DOI: 10.1016/j.clml.2015.08.083.Peer-Reviewed Original ResearchConceptsLower-risk myelodysplastic syndromesFirst-line therapyErythropoiesis-stimulating agentsFailure of treatmentTreatment failureInternational Working Group 2006 criteriaResponse rateSecond-line therapyMyelodysplastic syndrome patientsHigh response rateChromosome 5q deletionAzacitidine useHematologic improvementLenalidomide treatmentOverall survivalAnemic patientsMyelodysplastic syndromeSyndrome patientsLarge cohortLenalidomideAzacitidinePatientsLeukemic progressionClinical databaseTherapy